S'abonner

Hypoplastic Left Heart Syndrome with Mitral Stenosis and Aortic Atresia—Echocardiographic Findings and Early Outcomes - 03/06/24

Doi : 10.1016/j.echo.2024.02.008 
Hunter C. Wilson, MD a, Vikram Sood, MD b, Jennifer C. Romano, MD, MS b, Jeffrey D. Zampi, MD a, Jimmy C. Lu, MD a, Sunkyung Yu, MS a, Ray E. Lowery, BA a, Kellianne Kleeman, MD b, Sowmya Balasubramanian, MD a,
a Division of Pediatric Cardiology, University of Michigan, Ann Arbor, Michigan 
b Division of Thoracic Surgery, University of Michigan, Ann Arbor, Michigan 

Reprint requests: Sowmya Balasubramanian, MD, Division of Pediatric Cardiology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109.Division of Pediatric CardiologyUniversity of Michigan1500 East Medical Center DriveAnn ArborMI48109

Abstract

Background

Mitral stenosis/aortic atresia (MS/AA) has been reported as a high-risk variant of hypoplastic left heart syndrome (HLHS), potentially related to ventriculocoronary connections (VCCs) or endocardial fibroelastosis (EFE) and myocardial hypoperfusion. We aimed to identify echocardiographic and clinical factors associated with early death or transplant in this group.

Methods

Patients with HLHS MS/AA treated at our center between 2000 and 2020 were included. Pre—stage I palliation echocardiograms were reviewed. Certain imaging factors, such as determination of VCC, EFE, and measurement of tricuspid annular plane systolic excursion were measured from retrospective review of preoperative images; others were derived from clinical reports. Groups were compared according to primary outcome of death or transplant prior to stage II palliation.

Results

Of 141 patients included, 39 (27.7%) experienced a primary outcome. Ventriculocoronary connections were identified in 103 (73.0%) patients and EFE in 95 (67.4%) patients. Among imaging variables, smaller ascending aorta size (median, 2.2 [interquartile range (IQR) 1.7-2.8] vs 2.6 [2.2-3.4] mm, P = .01) was associated with primary outcome. There was similar frequency of VCC (74.4% vs 72.5%, P = .83), EFE (59.0% vs 72.5%, P = .19), moderate or greater tricuspid regurgitation (5.1% vs 5.9%, P = 1.00), and similar right ventricular systolic function (indexed tricuspid annular plane systolic excursion 32.5 ± 7.3 vs 31.4 ± 7.2 mm/m2, P = .47) in the primary outcome group compared to other patients. Clinical factors associated with primary outcome included lower birth weight (mean, 2.8 ± SD 0.8 vs 3.3 ± 0.5 kg, P = .0003), gestational age <37 weeks (31.6% vs 4.9%, P < .0001), longer cardiopulmonary bypass time (median, 112 [IQR, 93-162] vs 82 [71-119] minutes, P = .001), longer intensive care unit length of stay (median, 19 [IQR, 10-30] vs 10 [7-15] days, P = .001), and extracorporeal membrane oxygenation following stage I palliation (43.6% vs 8.8%, P < .0001). Presence of VCCs and EFE was not associated with death or transplant after controlling for birth weight and era of stage I palliation.

Conclusions

In one of the largest reported single-center cohorts of HLHS MS/AA, there were few pre–stage I palliation imaging characteristics associated with primary outcome. Imaging findings evaluated in this study, including the presence of VCC and/or EFE as determined using highly sensitive echocardiogram criteria, should not preclude intervention, although impact on long-term outcomes requires further evaluation.

Le texte complet de cet article est disponible en PDF.

Highlights

The literature is mixed on risk conferred by sinusoids in HLHS.
We find no association of sinusoids or other imaging variables with adverse outcome.
We identify several clinical factors associated with adverse outcome.
Presence of sinusoids alone should not preclude S1P.

Le texte complet de cet article est disponible en PDF.

Keywords : Congenital heart disease, Ventriculocoronary connections, Sinusoids, Hypoplastic left heart syndrome

Abbreviations : 2D, AA, AOR, BSA, ECMO, EFE, HLHS, ICU, IQR, LV, MS, S1P, S2P, TAPSE, VCC


Plan


© 2024  American Society of Echocardiography. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 37 - N° 6

P. 603-612 - juin 2024 Retour au numéro
Article précédent Article précédent
  • The Promise and Pitfalls of Three-Dimensional Vena Contracta for Mitral Regurgitation
  • Shantel Brissett, Gerard P. Aurigemma, Matthew W. Parker
| Article suivant Article suivant
  • Obstruction in Hypertrophic Cardiomyopathy: Many Faces
  • Muhannad Abbasi, Kevin C. Ong, D. Brian Newman, Joseph A. Dearani, Hartzell V. Schaff, Jeffrey B. Geske

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.